Q-omics provides the consensus-scored HMX1 profile across patient tissues and cancer cell-line models. HMX1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HMX1 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, HMX1 RNA expression shows 10,355 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUSC, and TGCT as cancer lineages where HMX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMX1 survival associations across molecular data types. HMX1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMX1 RNA expression–survival associations across cancer types. High HMX1 expression shows unfavorable associations in KIRP, OV, LIHC and LUAD, but favorable associations in PAAD and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HMX1 RNA expression.
This table summarizes HMX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HMX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMX1 shows lower tumor expression in THCA, KICH and STAD and higher tumor expression in LUSC, HNSC and PRAD. The LUSC box plot shows higher HMX1 RNA expression in tumor versus normal tissue (log2 FC = +0.558, t-test p < 0.001).
This table shows molecular features associated with HMX1 in patient tissues and cancer cell lines. In patient samples, HMX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HMX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OESOPHAGUS.
